Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for DNLI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 97.02M
March 31, 2026 103.85M
December 31, 2025 97.90M
September 30, 2025 101.95M
June 30, 2025 102.70M
March 31, 2025 116.23M
December 31, 2024 99.79M
September 30, 2024 98.24M
June 30, 2024 91.40M
March 31, 2024 107.02M
December 31, 2023 107.80M
September 30, 2023 89.74M
June 30, 2023 97.52M
March 31, 2023 128.82M
December 31, 2022 92.11M
September 30, 2022 87.79M
June 30, 2022 92.74M
March 31, 2022 86.10M
December 31, 2021 67.88M
September 30, 2021 71.56M
Date Value
June 30, 2021 65.71M
March 31, 2021 60.21M
December 31, 2020 54.74M
September 30, 2020 53.70M
June 30, 2020 53.15M
March 31, 2020 51.02M
December 31, 2019 51.55M
September 30, 2019 52.54M
June 30, 2019 50.08M
March 31, 2019 37.40M
December 31, 2018 39.91M
September 30, 2018 30.32M
June 30, 2018 44.23M
March 31, 2018 20.82M
December 31, 2017 17.66M
September 30, 2017 17.74M
June 30, 2017 19.00M
March 31, 2017 18.47M
December 31, 2016 16.04M
September 30, 2016 27.42M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 192.06M
Oncolytics Biotech, Inc. 4.262M
Sangamo Therapeutics, Inc. 26.57M
Sarepta Therapeutics, Inc. 91.26M
Anixa Biosciences, Inc. 1.258M